CNS – media

XOC PHARMACEUTICALS ANNOUNCES $30 MILLION SERIES A FINANCING LED BY NEA

Company to move forward with novel therapies for migraine and Parkinson’s disease
- Source: xocpharma
- 551
- February 27, 2018
CNS migraine Parkinson’s disease Series
US FDA Accepts Regulatory Submission for TAGRISSO (Osimertinib) in 1st-Line EGFR-Mutated Non-Small Cell Lung Cancer

AstraZeneca today announced that the US Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) for the use of TAGRISSO® (osimertinib), a third-generation, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) with clinical activity against central nervous system (CNS) metastases, in the 1st-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have EGFR mutations (exon 19 deletions or exon 21 (L858R) substitution mutations). The FDA has granted TAGRISSO Priority Review status, and previously granted Breakthrough Therapy Designation for TAGRISSO in the 1st-line treatment of patients with metastatic EGFR mutation-positive (EGFRm) NSCLC.
- Source: finance.yahoo
- 619
- December 19, 2017
AstraZeneca CNS FDA New Approvals NSCLC TAGRISSO®
Synpromics Announces Collaboration with UCL to Develop Revolutionary Gene Therapy for Parkinson’s Disease

Synpromics Ltd is pleased to announce a new collaboration with UCL to generate a range of synthetic gene promoters for the central nervous system (CNS), to develop a gene therapy for Parkinson’s disease.
- Source: Businesswire
- 482
- November 30, 2017
CNS Market Views Parkinson’s disease

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.